Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen, Altogen Biosystems, Thermo Fisher Scientific

Premium
Invitrogen has introduced two new RNAi research vectors.
 
The first, Block-iT HiPerform Lentiviral Pol-II miR RNAi expression system with Emerald Green Fluorescent Protein, can be used to deliver to non-dividing, primary, and hard-to-transfect cells, Invitrogen said.
 
The second, Block-iT Inducible Pol-II miR RNAi expression system, uses a tetracycline-inducible promoter that allows researchers to control RNAi expression.
 

 
Altogen Biosystems has introduced new contract research services for RNAi including transfection services, assay development and library screening, cloning and vector construction, stable cell-line generation, and RNAi and gene-targeting experiments.
 

 
Thermo Fisher Scientific has introduced the Dharmacon Accell siRNA, a novel form of siRNA that is absorbed directly by cells without the use of conventional delivery methods such as transfection reagents, viruses, or electroporation.
 
According to the company, the siRNA can silence genes in all cell types tested to date when mixed with the optimized Accell delivery media and added to cultured cells.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.